Clinical Trials Logo

Primary Immunodeficiency (PID) clinical trials

View clinical trials related to Primary Immunodeficiency (PID).

Filter by:
  • None
  • Page 1

NCT ID: NCT04528355 Recruiting - Clinical trials for Primary Immunodeficiency (PID)

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

PRO-RIC
Start date: August 20, 2020
Phase:
Study type: Observational

This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.

NCT ID: NCT02180763 Completed - Clinical trials for Primary Immunodeficiency (PID)

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Start date: April 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare satisfaction (LQI questionnaire, factor I: treatment interference) in PID patients receiving subcutaneous injections of Gammanorm® 165 mg/mL according to the delivery device.

NCT ID: NCT01962415 Recruiting - Clinical trials for Primary Immunodeficiency (PID)

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

HSCT+RIC
Start date: February 4, 2014
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). After transplant, subjects will be followed for late effects and for ongoing graft success.

NCT ID: NCT01287689 Completed - Clinical trials for Primary Immunodeficiency (PID)

Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study

SIGNS
Start date: July 2010
Phase: N/A
Study type: Observational [Patient Registry]

This non-interventional, epidemiological study assesses long-term outcomes in subjects receiving immunoglobulins (IgG) for any treatment purpose, irrespective of the regimen prescribed by the treating physician, under routine clinical conditions in Germany. Long-term outcome data are collected on patient characteristics in the various indications, drug utilization of intravenous and subcutaneous IgG (e.g. treatment and dosing patterns), effectiveness (i.e. number of infections), tolerability, health related quality of life, and economic variables (number of hospitalizations, sick-leave days etc.) with the possibility to estimate direct costs.

NCT ID: NCT00751621 Completed - Clinical trials for Primary Immunodeficiency (PID)

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Start date: August 2008
Phase: Phase 3
Study type: Interventional

This study is a continuation of the study ZLB06_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.

NCT ID: NCT00391131 Completed - Clinical trials for Primary Immunodeficiency (PID)

Subcutaneous Ig NextGen 16% in PID Patients

Start date: April 2007
Phase: Phase 3
Study type: Interventional

This study aims to assess the safety, tolerability, efficacy and pharmacokinetics of Ig NextGen 16% in people with antibody deficiency currently being treated with IntragamP. Ig NextGen 16% is a liquid immunoglobulin (antibody) preparation manufactured using predominately chromatographic techniques. Eligible patients will switch from monthly intravenous IntragamP therapy to weekly subcutaneous Ig NextGen 16% treatment. Initial hospital training will be required for subcutaneous administration and then the patient will perform the infusion in their own home, returning once a month for a supervised infusion. Patients will be monitored on the study for up to 10 months to assess blood IgG levels and rate of serious bacterial infections.